Form 4: Aura Biosciences' Chief Technology Officer Reports Acquisition and Disposal of Shares

Mark Plavsic, Chief Technology Officer of Aura Biosciences, reports acquiring shares through a restricted stock unit award and disposing of shares, along with acquiring stock options.

Summary

• Mark Plavsic, the Chief Technology Officer of Aura Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On February 3, 2025, Plavsic acquired 90,475 shares of common stock through a restricted stock unit (RSU) award under the company's 2021 Stock Option and Incentive Plan at $0.
• Each RSU represents the right to receive one share of Aura Biosciences' common stock, vesting in four equal annual installments starting February 15, 2026, contingent upon continued service.
• On the same date, Plavsic also disposed of 90,475 shares of common stock.
• Plavsic also acquired 59,525 stock options with an exercise price of $7.68, vesting 25% on February 3, 2026, and the remainder pro-rata over 36 months, also contingent upon continued service.
• Following these transactions, Plavsic directly owns 211,607 shares of common stock and 59,525 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs and stock options suggests confidence, but the disposal of shares tempers the positive outlook.

Positives

• The acquisition of shares via RSUs and stock options suggests confidence in the company's future performance by the CTO.

Negatives

• The disposal of 90,475 shares could be interpreted negatively, although the acquisition of RSUs and options may offset this concern.

Risks

• The vesting of RSUs and stock options is contingent upon continued service, creating a potential risk if the CTO were to leave the company before the vesting dates.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a multi-year commitment from the CTO, aligning his interests with the long-term success of the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biotechnology industry, used to attract and retain key personnel.
• Vesting schedules, such as the four-year annual installments for the RSUs and the combination of cliff vesting and monthly installments for the stock options, are typical in the industry.
• Comparable companies like BioNTech and Moderna also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they provide insight into the CTO's perspective on the company's value.
• Employees may view the RSU and stock option grants as a positive sign of the company's commitment to its leadership.

Key Dates